Inhibition of AMPK expression in skeletal muscle by systemic inflammation in COPD rats

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Qi, Yong ^a   Shang, Jun yi ^a   Ma, Li jun ^a   Sun, Bei bei ^a   Hu, Xin gang ^a   Liu, Bao ^a   Zhang, Guo jun ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; ANTIINFLAMMATORY AGENT; RIBONUCLEOTIDE; SIRT1 PROTEIN, RAT; SIRTUIN 1; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MUSCLE WEAKNESS; MYOPATHY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; RAT MODEL; SKELETAL MUSCLE; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTOR; WISTAR RAT;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MUSCLE WEAKNESS; MUSCLE, SKELETAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS, WISTAR; RIBONUCLEOTIDES; RNA, MESSENGER; SIRTUIN 1; STILBENES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928661405     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0156-4     Document Type: Article

References (29)

1. Lopez AD, Murray CC: The global burden of disease, 1990-2020. Nat Med. 1998, 4 (11): 1241-1243. 10.1038/3218.
2. Barnes PJ: Chronic obstructive pulmonary disease. N Engl J Med. 2000, 343 (4): 269-280. 10.1056/NEJM200007273430407. Review
3. Decramer M, Janssens W, Miravitlles M: Chronic obstructive pulmonary disease. Lancet. 2012, 379 (9823): 1341-1351. 10.1016/S0140-6736(11)60968-9.
4. Dumitru L, Iliescu A, Dinu H, Badea R, Savulescu S: Disability in COPD and chronic heart failure is the skeletal muscle the final common pathway?. Maedica (Buchar). 2013, 8 (2): 206-213.
5. Rabinovich RA, Vilaró J: Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2010, 16 (2): 123-133. 10.1097/MCP.0b013e328336438d.
6. Bernard S, Leblanc P, Whittom F, Carrier G, Jobin J, Belleau R, Maltais F: Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 158 (2): 629-634. 10.1164/ajrccm.158.2.9711023.
7. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, Gosker HR, Schols AM, Moxham J, Polkey MI, Wouters EF: The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010, 36 (1): 81-88. 10.1183/09031936.00104909.
8. Franssen FME, Broekhuizen R, Janssen PP, Wouters EF, Schols AM: Limb muscle dysfunction in COPD: effects of muscle wasting and exercise training. Med Sci Sports Exerc. 2005, 37 (1): 2-9. 10.1249/01.MSS.0000150082.59155.4F.
9. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M: Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003, 58 (9): 752-756. 10.1136/thorax.58.9.752.
10. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, Moore AJ, Moxham J, Polkey MI: Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007, 62 (2): 115-120. 10.1136/thx.2006.062026.
11. Schols AMWJ, Buurman WA, Staal-van Den Brekel AJ, Dentener MA, Wouters EF: Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996, 51 (8): 819-824. 10.1136/thx.51.8.819.
12. Singh B, Arora S, Khanna V: Association of severity of COPD with IgE and interleukin-1beta. Monaldi Arch Chest Dis. 2010, 73 (2): 86-87.
13. Petersen AMW, Penkowa M, Iversen M, Frydelund-Larsen L, Andersen JL, Mortensen J, Lange P, Pedersen BK: Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung. 2007, 185 (3): 161-171. 10.1007/s00408-007-9000-7.
14. Gan WQ, Man SFP, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004, 59 (7): 574-580. 10.1136/thx.2003.019588.
15. Carling D, Thornton C, Woods A, Sanders MJ: AMP-activated protein kinase: new regulation, new roles?. Biochem J. 2012, 445 (1): 11-27. 10.1042/BJ20120546.
16. Li Y, Li JS, Li WW, Tian YG, Lu XF, Jiang SL, Wang Y: Long-term effects of three Tiao-Bu Fei-Shen therapies on NF-ΚB/TGF-β1/smad2 signaling in rats with chronic obstructive pulmonary disease. BMC Complement Altern Med. 2014, 14 (1): 140-149. 10.1186/1472-6882-14-140.
17. Relationships between catabolic cytokines, hormones, energy balance, and muscle. JPEN J Parenter Enteral Nutr Roubenoff R. 2008, 32 (6): 630-632. 10.1177/0148607108324875.
18. Kumar A, Abbas W, Herbein G: TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?. Mediators Inflamm. 2013, 2013: 484378-10.1155/2013/484378.
19. Rossignol DA, Frye RE: A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012, 17 (4): 389-401. 10.1038/mp.2011.165.
20. Ming X, Brimacombe M, Chaaban J, Zimmerman-Bier B, Wagner GC: Autism spectrum disorders: concurrent clinical disorders. J Child Neurol. 2008, 23 (1): 6-13. 10.1177/0883073807307102.
21. Kim M, Hunter RW, Garcia-Menendez L, Gong G, Yang YY, Kolwicz SC, Xu J, Sakamoto K, Wang W, Tian R: Mutation in the γ2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ Res. 2014, 114 (6): 966-975. 10.1161/CIRCRESAHA.114.302364.
22. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, Ido Y: AMPK and SIRT1: a long-standing partnership?. Am J Physiol Endocrinol Metab. 2010, 4 (4): E751-E760. 10.1152/ajpendo.00745.2009.
23. Beg ZH, Allmann DW, Gibson DM: Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and with protein fractions of rat liver cytosol. Biochem Biophys Res Commun. 1973, 54 (4): 1362-1369. 10.1016/0006-291X(73)91137-6.
24. Carlson CA, Kim KH: Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. Arch Biochem Biophys. 1974, 164 (2): 478-489. 10.1016/0003-9861(74)90058-7.
25. Gómez-Zorita S, Fernández-Quintela A, Lasa A, Hijona E, Bujanda L, Portillo MP: Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats. Nutrition. 2013, 29 (11-12): 1374-1380. 10.1016/j.nut.2013.04.014.
26. Cantó C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M, Zierath JR, Auwerx J: Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 2010, 11 (3): 213-219. 10.1016/j.cmet.2010.02.006.
27. Wei H, Zhang Z, Saha A, Peng S, Chandra G, Quezado Z, Mukherjee AB: Disruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrol. Hum Mol Genet. 2011, 20 (6): 1111-1121. 10.1093/hmg/ddq555.
28. Nathan L, Ana P, Alvin JY, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA: SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15 (2): 675-690.
29. Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X, Zou H, Qiu J: Activation of Sirt1 by Resveratrol Inhibits TNF-α Induced Inflammation in Fibroblasts. Plos one. 2011, 11 (6): e27081-10.1371/journal.pone.0027081.